For some time now, Medius has noted that corporate acquisitions are in decline. And this month’s statistics bear that out – only one company acquisition was announced; that of Ocera Therapeutics by Mallincrodt. All the other five purchases in the top 20 were partial acquisitions, with buyers acquiring a division of a company or making a minority investment. Even the acquisition of the Stelic Institute by Mitsubishi Tanabe was preceded by Stelic splitting itself into two parts, with Mitsubishi Tanabe acquiring the gastro-intestinal assets alone.
| Licensor/Acquisition Target Licensee/Acquirer |
Deal Type | Headline ($m) |
|
Loxo Oncology Bayer |
Licence to develop and commercialise | 1,550 |
|
ZymeWorks Johnson & Johnson |
Licence to research, develop, and commercialise | 1,452 |
|
PeptiDream Bayer AG |
Drug discovery collaboration | 1,110 |
|
Principia Biopharma Sanofi |
Licence | 805 |
|
Halyard Health Owens & Minor |
Acquisition of division | 710 |
| Click here to view the top 20 deals for November 2017 | ||
The full report also contains:
- The harsh reality of liver disease
- The cost of not doing a deal
- Platform deals
- High scoring teams from big pharma
Want to read the complete report?
Interested in reading the past issues?
Add Your Response